Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Rhea-AI Summary
Immunic (Nasdaq: IMUX) announced that CEO Daniel Vitt, Ph.D. will participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on Thursday, December 4, 2025 at 9:35 am ET in Coral Gables, FL.
A webcast will be available in the Events and Presentations section of Immunic's investor website at https://ir.imux.com/events-and-presentations. Dr. Vitt and President/COO Jason Tardio will also hold one-on-one investor meetings during the conference; meeting requests can be made through Evercore ISI representatives or by contacting Jessica Breu at jessica.breu@imux.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IMUX declined 0.78%, reflecting a mild negative market reaction. This price movement removed approximately $663K from the company's valuation, bringing the market cap to $84M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IMUX was up 1.88% with mixed peer moves: ABOS +3.7%, ATRA +8%, while CRVO, IGMS and IRD showed declines, suggesting stock-specific factors rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | -0.8% | Announcement of CEO fireside chat and 1x1 meetings at Evercore ISI. |
| Nov 13 | Earnings and update | Negative | -6.2% | Q3 losses, limited liquidity, and need for additional capital disclosed. |
| Oct 29 | Conference schedule | Neutral | -5.0% | Planned participation in BIO-Europe and Jefferies healthcare meetings. |
| Oct 01 | Scientific conferences | Positive | +8.9% | Presentations on IMU-856 and vidofludimus plus investor events in October. |
| Sep 25 | Clinical data update | Positive | +2.2% | Statistically significant CALLIPER and favorable EMPhASIS MS data at ECTRIMS. |
Recent news, including conferences and clinical data, often saw aligned price reactions, with several conference announcements followed by negative moves and strong clinical updates drawing positive responses.
Over the last few months, Immunic has balanced clinical progress with financial strain. Positive multiple sclerosis data and conference participation in September–October 2025 were followed by a Q3 2025 update on net losses, liquidity pressure and going-concern language on November 13, 2025. The current Evercore ISI conference appearance on November 26, 2025 continues a pattern of active investor engagement alongside late-stage development efforts and capital needs.
Market Pulse Summary
This announcement highlights Immunic’s continued investor outreach, with a fireside chat and one-on-one meetings at a major healthcare conference on December 4, 2025. In recent months, the company reported late-stage multiple sclerosis data and Q3 2025 results that emphasized both clinical progress and liquidity pressure. Investors may focus on how management frames funding plans, development timelines and upcoming milestones during these conference interactions.
AI-generated analysis. Not financial advice.
A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu at: jessica.breu@imux.com.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december-302623149.html
SOURCE Immunic, Inc.
FAQ
When will Immunic (IMUX) present at the Evercore ISI Healthcare Conference?
Where can investors watch the Immunic (IMUX) webcast for the December 4, 2025 fireside chat?
Who from Immunic (IMUX) will attend investor meetings at the Evercore ISI conference?
How can investors schedule a meeting with Immunic (IMUX) at the December 2025 Evercore ISI conference?
What are the dates and location of the 8th Annual Evercore ISI Healthcare Conference where IMUX will appear?
Will Immunic (IMUX) provide a replay of the December 4, 2025 webcast?
